Evan Scott, Ph.D. A preeminent nanomedicine expert in early cancer detection and novel therapies, Dr. Scott heads up the University of Virginia's Institute for Nanoscale Scientific and Technological Advanced Research (nanoSTAR). Dr. Scott uses nanotechnology – designing and manufacturing minute devices and structures – to fight cancer – addressing it from a biomedical engineering standpoint. Scott and his team are developing new nanomaterials and drug delivery methods focusing on directing nanoparticles to specific parts of the body and controlling their interactions with the immune system treatments for cancer to save, extend and improve patients' lives. At CanceRx, Dr. Scott focuses on identifying promising clinical trials for early detection and treatment by delivering nanoparticle formulations that modulate the immune system to enhance immunotherapy treatments.

Dr. Scott earned his Ph.D. in biomedical engineering at Washington University in St. Louis and his bachelor's in biomedical engineering at Brown University. He did postdoctoral work at the Swiss Federal Institute of Technology (EPFL) in Lausanne. Dr. Scott has authored over 80 publications, holds 21 patents, and is the founder and CEO of SNC Therapeutics, Inc., an AbbVie portfolio startup company focused on cancer nanotherapy.